Does Wellcare Cover Dupixent?
The verdict
Covered on most plans
Wellcare (Centene) covers Dupixent on the specialty tier with prior authorization and step therapy across its Medicare Part D and Medicaid managed-care plans. For Part D members, coinsurance is typically 25–33% after the deductible, capped at $2,100 for the year under the 2026 Part D out-of-pocket limit. For Medicaid members, cost-share is nominal. The Dupixent MyWay copay card is not available for Medicare or Medicaid beneficiaries. Verify on your Wellcare plan drug list.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Wellcare (Centene) primarily serves Medicare Part D and Medicaid managed-care members; Dupixent is covered on the specialty tier with PA across both lines of business.
Wellcare/Centene plan drug list
The 2026 Part D out-of-pocket cap of $2,100 protects Medicare members; dual-eligible members may also have Medicaid cover their Part D cost-share.
CMS Medicare Part D 2026 parameters
About 79% of Medicare Part D Dupixent recipients pay $0–$100/month; the Dupixent MyWay copay card is not available for Medicare or Medicaid beneficiaries.
Sanofi/Regeneron Dupixent coverage data
Medicare vs. commercial coverage
Whether Wellcare covers Dupixent depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D (Wellcare PDP/MA-PD): Dupixent is covered on the specialty tier with PA and step therapy, dispensed through a specialty pharmacy. Coinsurance is typically 25–33% after the deductible. The 2026 Part D out-of-pocket cap of $2,100 limits total annual drug exposure. For dual-eligible members (Medicare and Medicaid), Medicaid may cover Part D cost-share. The Dupixent MyWay savings card is not available to Medicare beneficiaries. Dupixent can also shift to Medicare Part B coverage when clinic-administered rather than self-injected.
Commercial / Employer
Group & marketplace plans
Wellcare has minimal commercial/employer plan presence; this insurer primarily serves Medicare Part D and Medicaid managed-care populations. ACA/Individual coverage is limited — where offered, Dupixent is on the specialty tier with PA. Medicaid (Centene managed care): covered for FDA-approved indications per state preferred-drug list with PA and step therapy; nominal cost-share of $0–$4. Because Centene is a federation of state Medicaid contracts, specifics vary by state — verify on your Wellcare drug list or state Medicaid PDL.
The 4 boxes you must tick to get approved
Commercial plans that will consider Dupixent require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 4 requirements selected. Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Dupixent actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
List price approximately $3,993 per carton of 2 injections (January 2025 estimate); average retail approximately $5,350–$5,377/month for two 300 mg/2 mL pens. Treat as an estimate — verify with pharmacy.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: typically 25–33% coinsurance after the deductible, capped at $2,100 for the year (2026 cap). Medicaid: $0–$4 nominal cost-share per state plan. For dual-eligible members, Medicaid may cover the Part D coinsurance.
Typical monthly copay once prior authorization is approved.
Bridge program
Dupixent MyWay copay card is not available to Medicare or Medicaid beneficiaries. Commercially insured patients (rare on Wellcare) may be eligible — visit dupixent.com. Patients who cannot afford treatment may qualify for Sanofi/Regeneron's patient-assistance program.
Reduced copay through the assistance program, where eligible.
All figures are estimates and vary by plan and state. Confirm your specific cost-share with Wellcare or your Medicaid case manager before filling.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Look up your Wellcare drug list or state Medicaid PDL
Visit wellcare.com or call the member services number on your Wellcare card. Search for 'dupilumab' or 'Dupixent' on your plan's drug list. Because Centene administers state Medicaid contracts, also check your state's Medicaid preferred-drug list (PDL) for formulary placement and step-therapy rules.
- 2
Contact Wellcare member services about PA requirements
Call the number on your Wellcare member ID card to ask about the specific prior-authorization criteria and specialty-pharmacy network for Dupixent. For Medicaid members, also ask whether your state plan requires additional step therapy before approval.
- 3
Have your specialist submit the prior authorization
Ask your allergist, dermatologist, or other treating specialist to submit the PA request. The submission should include your diagnosis, prior-treatment history (topicals or other biologics tried), and the indication for Dupixent. Dual-eligible members should also verify that Medicaid coordination is in place to cover their Part D cost-share.
Options if Wellcare won't cover Dupixent
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Dupixent patient-assistance program (non-Medicare/Medicaid)
Sanofi/Regeneron offers a patient-assistance program for uninsured or underinsured patients who do not qualify for the commercial copay card. Visit dupixent.com to check eligibility.
Tralokinumab (Adbry)
Another IL-13 biologic for moderate-to-severe atopic dermatitis. May be covered on your Wellcare or Medicaid plan drug list — check your specific formulary.
State Medicaid extra-help programs
For dual-eligible members with both Medicare and Medicaid, the Low-Income Subsidy (Extra Help) program can further reduce Part D cost-sharing. Contact your state Medicaid office or Social Security Administration.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
Yes. Wellcare's Medicaid managed-care plans cover Dupixent for FDA-approved indications per the state preferred-drug list, with PA and step therapy. Cost-share is nominal — typically $0–$4 per fill. Because Centene administers Medicaid contracts across multiple states, exact coverage requirements vary by state. Verify on your state's Wellcare Medicaid drug list or PDL.
On Wellcare Medicare Part D, Dupixent coinsurance is typically 25–33% after the deductible. The 2026 Part D out-of-pocket cap of $2,100 limits total annual spending. For dual-eligible members (Medicare and Medicaid), Medicaid often covers the Part D cost-share, bringing out-of-pocket cost close to zero. The Dupixent MyWay copay card is not available for Medicare beneficiaries.
Not for Medicare or Medicaid members, which make up the vast majority of Wellcare's membership. The Dupixent MyWay card is available only to commercially insured patients — a rare status on Wellcare. If you have commercial Wellcare coverage, visit dupixent.com to check eligibility. Medicare and Medicaid members may qualify for Sanofi/Regeneron's patient-assistance program instead.
Yes. Wellcare's Medicare Part D and Medicaid plans require indication-specific step therapy. For atopic dermatitis, this typically means documenting a trial of prescription-strength topical corticosteroids and other topical treatments before Dupixent is approved. For asthma, a trial of another add-on biologic is usually required. Step-therapy specifics vary by state Medicaid plan — verify requirements with Wellcare or your prescriber.
Yes. Dupixent is usually a Part D self-injected specialty drug, but when administered in a clinic by a healthcare provider, it can shift to Medicare Part B coverage. Under Part B, cost-sharing is 20% coinsurance after the Part B deductible rather than specialty-tier Part D coinsurance, and the $2,100 Part D OOP cap would not apply. Confirm site-of-care billing with your Wellcare plan and treating provider.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.